SNMMI Curriculum VL

Integrating PSMA-based Fluorescence Molecular Imaging During Robotic Prostatectomy - Hao Nguyen

Details
This webinar organized in collaboration with The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Prostate Cancer Working Group and faculty from the University of California, San Francisco (UCSF), Hao Nguyen, MD, PhD, details the role of PSMA pet scans and how to integrate this imaging technique into the operating room during radical prostatectomy. Biographies: Hao Nguyen, MD, Ph.D., As...

Introduction to PET PSMA Gallium-68 PSMA-11 for Diagnostic Imaging of Prostate Cancer - Tom Hope

Details
This webinar organized in collaboration with The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Prostate Cancer Working Group and faculty from the University of California, San Francisco (UCSF), Tom Hope, MD provides a detailed presentation of the background of PSMA PET for patients with prostate cancer and shares recent work by faculty at UCSF on Gallium-68 PSMA-11. Biographies: Tom...

Management of Oligometastatic Prostate Cancer: From Imaging to Therapy - Felix Feng

Details
In this webinar organized in collaboration with The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Prostate Cancer Working Group, and faculty from the University of California, San Francisco (UCSF), Felix Feng, MD presents on advances in molecular imaging for the management of oligometastatic prostate cancer. Biographies: Felix Y. Feng, MD, Professor of Radiation Oncology; Urology; an...

Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell

Details
Prostate Cancer Outreach Webinar - Hosted by The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Prostate Cancer Working Group, and faculty from the University of California, San Francisco (UCSF) Molecular imaging and radionuclide therapies play an important role in the management of patients with prostate cancer. Recent advances are allowing for increased precision in both diagnosis a...

Modulation of PSMA Expression by Androgen Deprivation Therapy (ADT) - Louise Emmett

Details
Louise Emmett presents on the modulation of prostate-specific membrane antigen (PSMA) expression by androgen deprivation therapy (ADT). The study is comprised of serial PSMA PET in men with either hormone-sensitive or castrate-resistant prostate cancer commencing androgen blockade. PSMA may be targeted for either diagnostic and therapeutic purposes in the management of prostate cancer. Dr. Emmett...

Bone Targeted Theranostics with 18F-NaF/ 223Ra Cl2 in Prostate Cancer - Hossein Jadvar

Details
Hossein Jadvar presents on the use of sodium fluoride and radium-223 as a theranostic pair in the treatment of patients with metastatic prostate cancer. 18 F-sodium fluoride has experienced a remarkable recent renaissance in the management of neuroendocrine tumors and prostate cancer. Dr. Jadvar presents this information during the annual meeting of the Society of Nuclear Medicine and Molecular Im...

Non-PSMA Based Theranostics in Prostate Cancer - Andrei Iagaru

Details
Andrei Iagaru speaks on non-PSMA based theranostics in prostate cancer. Dr. Iagaru covers gastrin-releasing peptide receptors, part of the bombesin family, which are overexpressed in many cancers including prostate cancer. Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic or both diagnostic and therapeutic purposes is a promising approach in oncological appl...

Radiotherapy Planning in Prostate Cancer Patients - Matteo Sepulcri and Laura Evangelista

Details
Matteo Sepulcri and Laura Evangelista present on radiotherapy in prostate cancer patients. Together they touch on subjects such as radiotherapy treatments for prostate cancer and the role of PET/CT in different stages of prostate cancer. This presentation took place as part of the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting. Biographies: Matteo Sepulcri, Radiation Onco...

Reproducibility and Repeatability of Quantitative FDHT Uptake Metrics in CRPC - Andrew Scott

Details
Andrew Scott, MD presented a multinational trial looking at a fluorodihydrotestosterone (FDHT) in patients with castration-resistant prostate cancer on behalf of colleagues from a number of institutions. The intent was that they would look at whether or not this was a test which could be reliably introduced in individual patients at multiple centers in multiple continents, and whether or not there...

Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni

Details
Where in this treatment regimen would you place lutetium-177-PSMA radioligand therapy? This was the question Harshad Kulkarni, MD posed to the audience at the start of his presentation. The aim of the study which he was presenting during this Society of Nuclear Medicine and Molecular Imaging presentation was to determine the influence of timing of lutetium PSMA radioligand therapy in metastatic pr...
email news signup